Abstract

The Molecular Biology and Vector Core (Core B) will have the following functions: 1) maintain inventory of recombinant DNA vectors, 2)perform large-scale plasmid preps, 3) perform plasmid cloning, 4) perform HEK 293 cell transfections, 5) perform large-scale adenovirus preps, 6) characterize recombinant adenoviruses (laboratory and GMP grade), 7) analyze potency of adenovirus following each patient injection, 8) monitor presence of adenoviral DNA in patient's blood using PCR/Southern blot assay. The Molecular Biology and Vector Core will provide laboratory grade, CsCl gradient-purified adenovirus to Projects 1 and 2. Clinical grade (GMP) adenovirus will be manufactured at the Baylor Gene Vector Laboratory. Clinical grade virus will be characterized extensively in the Molecular Biology and Vector Core before it is used in Project 3.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA097012-01A2
Application #
6990180
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-08-01
Project End
2009-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
1
Fiscal Year
2004
Total Cost
$305,202
Indirect Cost

  Institution

Name
Henry Ford Health System
Department
Type
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202

  Publications

Freytag, Svend O; Stricker, Hans; Lu, Mei et al. (2014) Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 89:268-76
Lu, Mei; Freytag, Svend O; Stricker, Hans et al. (2011) Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). Contemp Clin Trials 32:453-60
Barton, Kenneth N; Stricker, Hans; Elshaikh, Mohamed A et al. (2011) Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther 19:1353-9
Kumar, Sanath; Freytag, Svend O; Barton, Kenneth N et al. (2010) A novel method of boron delivery using sodium iodide symporter for boron neutron capture therapy. J Radiat Res 51:621-6
Siddiqui, Farzan; Kolozsvary, Andrew; Barton, Kenneth N et al. (2009) Does hyperthermia increase adenoviral transgene expression or dissemination in tumors? Int J Hyperthermia 25:273-9
Freytag, Svend O; Stricker, Hans; Peabody, James et al. (2007) Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15:636-42
Freytag, Svend O; Barton, Kenneth N; Brown, Stephen L et al. (2007) Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 15:1600-6
Brown, Stephen L; Freytag, Svend O; Barton, Kenneth N et al. (2007) Reporter gene imaging using radiographic contrast from nonradioactive iodide sequestered by the sodium-iodide symporter. Contrast Media Mol Imaging 2:240-7
Barton, Kenneth N; Freytag, Svend O; Nurushev, Teamour et al. (2007) A model for optimizing adenoviral delivery in human cancer gene therapy trials. Hum Gene Ther 18:562-72
Freytag, Svend O; Movsas, Benjamin; Aref, Ibrahim et al. (2007) Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15:1016-23

Showing the most recent 10 out of 15 publications